Current and emerging treatment modalities for metastatic castration-resistant prostate cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
BJU INTERNATIONAL
Volume 107, Issue -, Pages 13-20
Publisher
Wiley
Online
2011-03-08
DOI
10.1111/j.1464-410x.2010.10036.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
- (2010) Jean-Christophe Eymard et al. BJU INTERNATIONAL
- Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
- (2010) Nicholas D. James et al. BJU INTERNATIONAL
- A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations
- (2010) E. Efstathiou et al. CLINICAL CANCER RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
- (2009) A. Horwich et al. ANNALS OF ONCOLOGY
- Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide
- (2009) Cigdem Erten et al. BJU INTERNATIONAL
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2009) E. Y. Yu et al. CLINICAL CANCER RESEARCH
- Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment
- (2009) John M. Fitzpatrick et al. EUROPEAN UROLOGY SUPPLEMENTS
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
- (2009) D.R. Shepard et al. JOURNAL OF UROLOGY
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs
- (2009) Catherine Sánchez et al. PROSTATE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data
- (2008) Cristiana Lo Nigro et al. BJU INTERNATIONAL
- Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial
- (2008) Orazio Caffo et al. BJU INTERNATIONAL
- Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
- (2008) S. I. Park et al. CANCER RESEARCH
- Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
- (2008) D. R. Berthold et al. CLINICAL CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
- (2008) Nicholas D. James et al. EUROPEAN UROLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Androgen Ablation With or Without Three Cycles of Systemic Chemotherapy for Advanced Prostate Cancer
- (2008) Randall E. Millikan et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer
- (2008) Kim N. Chi et al. JOURNAL OF UROLOGY
- Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone
- (2008) Orazio Caffo et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer
- (2007) Tomasz M. Beer et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started